6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $109M | -$10M | 0.0% | -15.8% | -$105M | — | $62M |
| 2024 | $7M | -$127M | 0.0% | -2096.5% | -$110M | — | $58M |
| 2023 | $2M | -$137M | 0.0% | -6556.9% | -$102M | — | $47M |
| 2022 | $5M | -$131M | 0.0% | -2574.2% | -$17M | $10M | $84M |
| 2021 | — | -$96M | — | — | -$134M | $10M | $56M |
| 2020 | — | -$54M | — | — | -$51M | $10M | $27M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$22M | — | — | -$26M | — | $51M |
| Dec '25 | $0 | -$19M | — | — | -$16M | — | $62M |
| Sep '25 | $0 | -$34M | — | — | -$26M | — | $56M |
| Jun '25 | $0 | -$33M | — | — | -$28M | — | $57M |
| Mar '25 | $109M | $77M | 0.0% | 67.9% | -$35M | — | $52M |
| Dec '24 | $4M | -$36M | 0.0% | -893.5% | — | — | $58M |
| Sep '24 | $791000 | -$31M | 0.0% | -4398.1% | — | — | $53M |
| Jun '24 | $771000 | -$31M | 0.0% | -4507.8% | -$28M | — | $41M |
| Mar '24 | $855000 | -$28M | 0.0% | -3661.9% | -$31M | — | $47M |
| Dec '23 | $268000 | -$39M | 0.0% | -16329.1% | -$27M | — | $47M |
| Sep '23 | $148000 | -$33M | 0.0% | -24071.6% | -$17M | — | $55M |
| Jun '23 | $99000 | -$33M | 0.0% | -35431.3% | -$24M | — | $64M |
| Mar '23 | $2M | -$31M | 0.0% | -1865.2% | -$34M | $10M | $87M |
| Dec '22 | $521000 | -$32M | 0.0% | -6392.7% | -$29M | $10M | $84M |
| Sep '22 | $2M | -$31M | 0.0% | -1427.1% | -$34M | $10M | $111M |
| Jun '22 | $1M | -$31M | 0.0% | -2245.8% | -$36M | $10M | $113M |
| Mar '22 | $1M | -$38M | 0.0% | -3538.4% | $83M | $10M | $126M |
| Dec '21 | — | -$28M | — | — | -$41M | $10M | $56M |
| Sep '21 | — | -$26M | — | — | -$40M | $10M | $101M |
| Jun '21 | — | -$23M | — | — | -$29M | $10M | $272M |
How the market has priced IPSC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Century Therapeutics, Inc.'s revenue has grown 175.9% per year. These are computed facts, not advice.
As of FY2025, Century Therapeutics, Inc. reported — of total debt against $62M of cash.
In FY2025, gross margin was —, operating margin -15.8%, and net margin -8.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.